Released Mar 4, 2020, after the close
10-K filed Mar 4, 2020, 64 days after period end · 0001564590-20-008696
Q4 2019 · 10-K
Revenue$4.77M$4.77M +27.6% vs Q4 2018+12.7% vs Q3 2019
Net Income-$27.08M-$27.08M N/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.99-$0.99 N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$28,684,000N/M
Operating Cash Flowderived-$20,528,000N/M
Free Cash Flowderived-$20,543,000N/M
Margins · derived
Operating margin-601.7%+103.0 pt vs Q4 2018
Net margin-568.2%+132.3 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $4.77M | $3.74M | $3.32M | — |
| Net Income | -$27.08M | -$26.16M | -$3.01M | -$11.55M |
| EPS Diluted | -$0.99 | -$1.03 | -$160.00 | -$0.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR